Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

Lupin secures SBTi validation for emission reduction targets

Lupin arm Novel Labs bags USFDA nod for Diazepam Rectal Gel

Ruchika Sharma2 Jun 2023 12:30 PM IST

Mumbai: Pharma major, Lupin Limited, has announced that its wholly-owned subsidiary, Novel Laboratories Inc., based in Somerset, New Jersey, has...

CDSCO nod to AstraZeneca cancer drug Tremelimumab

Ruchika Sharma2 Jun 2023 11:53 AM IST

The approval paves the way for the launch of Tremelimumab solution of 20 mg/ml (25 mg/1.25 ml and 300 mg/15 ml presentations in single-dose vials) in...

AstraZeneca Pharma India names Bhavana Agrawal as new CFO

Ruchika Sharma1 Jun 2023 5:30 PM IST

Bangalore: AstraZeneca Pharma India Ltd., a leading biopharmaceutical company, has announced the appointment of Bhavana Agrawal as Chief Finance...

Natco Pharma gets 7 USFDA observations for Kothur Pharma Division

USFDA inspection: Caplin Steriles gets 4 observations for Gummidipoondi site

Ruchika Sharma1 Jun 2023 2:42 PM IST

Chennai: Caplin Steriles Limited has announced that the United States Food and Drug Administration (USFDA) has issued four...

CDSCO Panel Approves Phase IV Protocol Amendment for Bristol-Myers Squibbs Mavacamten Study

Bristol Myers Squibb gets USFDA priority review for lung cancer treatment Repotrectinib

Ruchika Sharma1 Jun 2023 2:00 PM IST

Non-small cell lung cancer is one of the most common types of lung cancer, representing up to 84% of diagnoses.

Laurus Labs to buy additional stake of 7.24 percent in Immunoadoptive Cell Therapy for Rs 80 Crore

Ruchika Sharma1 Jun 2023 1:00 PM IST

Additionally, some promoters and senior management of Laurus Labs would also acquire in ImmunoACT for a 0.54% stake (before this investment) for...

Pfizer bags USFDA nod for RSV vaccine Abrysvo for older adults

Ruchika Sharma1 Jun 2023 12:00 PM IST

The FDA's decision is based on the data from the pivotal Phase 3 clinical trial (NCT05035212) RENOIR (RSV vaccine Efficacy study iNOlder adults...

Novartis opens new radioligand therapy manufacturing facility in California

Novartis Cosentyx gets European Commission nod for use in adults with hidradenitis suppurativa

Ruchika Sharma1 Jun 2023 11:00 AM IST

A regulatory decision from the US Food and Drug Administration is expected later this year.

Budget Quotes - Mankind Pharma, Bharat Serum and Vaccines & Park Medi World

Mankind Pharma PAT up 52 percent at Rs 294 crore in Q4

Ruchika Sharma1 Jun 2023 10:00 AM IST

New Delhi: Mankind Pharma has reported 52 percent increase in consolidated profit after tax (PAT) at Rs 294 crore for March quarter 2022-23, aided by...

Lupin Nagpur facility completes USFDA inspection

Lupin gets USFDA nod for generic equivalent of Ocaliva Tablets

Ruchika Sharma31 May 2023 5:30 PM IST

Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug Administration (U.S....

Janssen seeks USFDA nod for single tablet combination therapy of Macitentan, Tadalafil for Pulmonary Arterial Hypertension

Ruchika Sharma31 May 2023 3:30 PM IST

Raritan: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a New Drug Application (NDA) to the U.S. Food...

Torrent Pharma Appoints Former Cipla Global CTO Geena Malhotra as Chief Technology Officer

Torrent Pharma posts PAT at Rs 287 crore in Q4

Ruchika Sharma31 May 2023 2:30 PM IST

The board also approved a final dividend of Rs 8 per share of Rs 5 each.

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok